Reversal of left ventricular hypertrophy: What have recent trials taught us?

American Journal of Cardiovascular Drugs

Volumn 4, Issue 6, 2004, Pages 369-378

  Verdecchia, Paolo ^a   Angeli, Fabio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOSARTAN; NIFEDIPINE; PRAZOSIN;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE WALL; HUMAN; HYPERTENSION; MONOTHERAPY; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROBABILITY; QUALITY CONTROL; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 10444271738     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200404060-00005     Document Type: Review

References (98)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65
2. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-8
3. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6
4. Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039-44
5. Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. Am J Med 1983; 75: 4-11
6. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117: 831-6
7. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52
8. Mensah GA, Pappas TW, Koren MJ, et al. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens 1993; 11: 1429-40
9. Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. Am J Med 1984; 77: 18-22
10. McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317: 787-92
11. Haider AW, Larson MG, Benjamin EJ, et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32: 1454-9
12. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardization, and comparison to other methods. Hypertension 1987; 9 Suppl. II: II9-26
13. Devereux RB, Casale PN, Wallerson DC, et al. Cost-effectiveness of echocardiography and electrocardiography for detection of left ventricular hypertrophy in patients with systemic hypertension. Hypertension 1987; 9 (2 Pt 2): II69-76
14. Devereux RB, Dahlöf B. Criteria for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens 1994; 8: 735-9
15. Gottdiener JS, Livengood SV, Meyer PS, et al. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function. J Am Coll Cardiol 1995; 25: 424-30
16. de Simone G, Muiesan ML, Ganau A, et al. Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial (Reliability of M-mode Echocardiographic Studies). Working Group on Heart and Hypertension of the Italian Society of Hypertension. J Hypertens 1999; 17 (12 Pt 2): 1955-63
17. Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5mg versus enalapril 20mg: the LIVE study. J Hypertens 2000; 18: 1465-75
18. Gosse P, Dubourg O, Guéret P. Influence of left ventricular geometry pattern in left ventricular hypertrophy changes after 1 year of treatment in the LIVE study. J Hypertens 2000; 18 Suppl. 4: P2-23
19. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-62
20. de Simone G, Palmieri V. Left ventricular hypertrophy in hypertension as a predictor of coronary events: relation to geometry. Curr Opin Nephrol Hypertens 2002; 11: 215-20
21. Hammond IW, Devereux RB, Alderman MH, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639-50
22. Chambers J. Left ventricular hypertrophy. BMJ 1995; 311: 273-4
23. Grossman E, Shemesh J, Shamiss A, et al. Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992; 152: 1001-4
24. Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J 2004; 147: 218-23
25. Devereux RB, Palmieri V, Liu JE, et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 2002; 20: 1445-50
26. Gosse P, Guez D, Guéret P, et al. Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16: 531-5
27. Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive subjects with normal left ventricular mass. J Am Coll Cardiol 1995; 25: 871-8
28. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996; 78: 197-202
29. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879-84
30. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635-40
31. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
32. Fagard RH, Staessen JA, Thijs L. Relationship between changes in left ventricular mass and in clinic and ambulatory pressure in response to antihypertensive therapy. J Hypertens 1997; 15: 1493-502
33. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy: Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. SAMPLE study group. Circulation 1997; 95: 1464-70
34. Skudicky D, Sareli P, Libhaber E, et al. Relationship between treatment-induced changes in left ventricular mass and blood pressure in black African hypertensive patients. Circulation 2002; 105: 830-6
35. Messerli FH, Nunez BD, Nunex MM, et al. Hypertension and sudden death: disparate effect of calcium entry blocker and diuretic therapy on cardiac dysrhythmias. Arch Intern Med 1989; 149: 1263-7
36. Motz W, Strauer BE. Therapy of hypertensive cardiac hypertrophy and impaired coronary microcirculation. J Cardiovasc Pharmacol 1994; 24 Suppl. 1: S34-8
37. Franz IW, Tonnesmann U, Muller JF. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens 1998; 11: 631-9
38. Haneda T, Ogawa Y, Kato J, et al. Effect of celiprolol on cardiac hypertrophy in hypertension. Hypertens Res 2000; 23: 467-74
39. Wachtell K, Palmieri V, Olsen MH et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) study. Circulation 2002; 106: 227-32
40. Fouad FM, Nakashira P, Tarazi RS, et al. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Am J Cardiol 1982; 49: 795-9
41. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-93
42. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001; 104: 1615-21
43. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-5
44. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54
45. Cipriano C, Gosse P, Bemurat L, et al. Prognostic value of left ventricular mass and its evolution during treatment in the Bordeaux cohort of hypertensive patients. Am J Hypertens 2001; 14: 524-9
46. Koren MJ, Ulin RJ, Koren AT, et al. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15: 1021-8
47. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64
48. Ganau A, Devereux RB, Pickering TG, et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 1990; 81: 25-36
49. Young W, Gofman JW, Tandy R. The quantitation of atherosclerosis: quantitative aspects of the relationship of blood pressure and atherosclerosis. Am J Cardiol 1960; 6: 294-9
50. Roman MJ, Saba PS, Pini R, et al. Parallel cardiac and vascular adaptation in hypertension. Circulation 1992; 86: 1909-18
51. Khattar RS, Senior R, Swales JD, et al. Value of ambulatory intra-arterial blood pressure monitoring in the long-term prediction of left ventricular hypertrophy and carotid atherosclerosis in essential hypertension. J Hum Hypertens 1999; 13: 111-6
52. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces cardiac hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-21
53. Diez J, Laviades C, Martinez E, et al. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens 1995; 13: 349-55
54. Verdecchia P, Reboldi G, Schillaci G, et al. Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-7
55. Rajala U, Laakso M, Paivansalo M, et al. Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab 2002; 87: 5092-7
56. Urbina EM, Srinivasan SR, Tang R, et al. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults: the Bogalusa Heart Study. Am J Cardiol 2002; 90: 953-8
57. Watanabe S, Okura T, Kitami Y, et al. Carotid hemodynamic alterations in hypertensive patients with insulin resistance. Am J Hypertens 2002; 15: 851-6
58. Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153: 937-42
59. Sadoshima J, Xu Y, Slayter HS, et al. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac muscle in vitro. Cell 1993; 75: 977-84
60. Sadoshima J, Izumo S. Molecular characterization of angiotensin II: induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype. Circ Res 1993; 73: 413-23
61. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105: 1605-12
62. Nickenig G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens 2002; 16 Suppl. 3: S26-33
63. Weiss D, Kools JJ, Taylor WR. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 2001; 103: 448-54
64. Lerman A, Edwards BS, Hallett JW, et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001
65. Ihling C, Szombathy T, Bohrmann B, et al. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation 2001; 104: 864-9
66. Ichikawa KI, Hidai C, Okuda C, et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996; 27: 1286-91
67. Jullien V, Gosse P, Ansoborlo P, et al. Relationship between left ventricular mass and serum cholesterol level in the untreated hypertensive. J Hypertens 1998; 16: 1043-7
68. Schillaci G, Vaudo G, Reboldi G, et al. High-density lipoprotein cholesterol and left ventricular hypertrophy in essential hypertension. J Hypertens 2001; 19: 2265-70
69. Devereux RB, Drayer JI, Chien S, et al. Whole blood viscosity as a determinant of cardiac hypertrophy in systemic hypertension. Am J Cardiol 1984; 54: 592-5
70. Levenson J, Gariepy J, Del-Pino M, et al. Association of plasma viscosity and carotid thickening in a French working cohort. Am J Hypertens 2000; 13: 753-8
71. Kohara K, Zhao B, Jiang Y, et al. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol 1999; 83: 367-70
72. Bikkina M, Levy D, Evans JC, et al. Left ventricular mass and risk of stroke in an elderly cohort: the Framingham Heart Study. JAMA 1994; 272: 33-6
73. Aronow WS, Ahn C, Kronzon I, et al. Association of extracranial carotid arterial disease, prior atherothrombotic brain infarction, systemic hypertension, and left ventricular hypertrophy with the incidence of new atherothrombotic brain infarction at 45-month follow-up in 1482 older patients. Am J Cardiol 1997; 79: 991-3
74. Zabalgoitia M, Berning J, Koren MJ, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy: the LIFE study. Am J Cardiol 2001; 88: 646-50
75. de Simone G, Pasanisi F, Contaldo F. Link of nonhemodynamic factors to hemodynamic determinants of left ventricular hypertrophy. Hypertension 2001; 38: 13-8
76. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-93
77. Böcker W, Hupf H, Grimm D, et al. Effects of indapamide on regression of pressure overload hypertrophy in rat hearts. J Hypertens 2000; 18 Suppl. 4: S1-8
78. Gottdiener JS, Reda DJ, Massie BM, et al. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997; 95: 2007-14
79. Devereux RB. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy? Circulation 1997; 95: 1983-5
80. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-13
81. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6
82. Sacks HS, Berrier J, Reitman D, et al. Meta-analysis of randomized controlled trials. N Engl J Med 1987; 316: 450-5
83. Sheridan DJ, Kingsbury MP, Flores NA. Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives? Br J Clin Pharmacol 1999; 47: 125-30
84. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706
85. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248-54
86. Gosse P, Dubourg O, Gueret P. Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. J Hypertens 2003; 21: 217-21
87. Devereux RB, Wachtell K, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy: treatment effects and prognostic implications in the LIFE trial. J Hypertens 2002; 20 Suppl. 4: S5
88. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial. Circulation 2004; 110: 1456-62
89. 2003 European Society of Hypertension: European Society of Cardiology Guidelines on the management of arterial hypertension. J Hypertens 2003; 21: 1011-59
90. Mallion J-M, Asmar R, Boutelant S, et al. Twenty-four hour antihypertensive efficacy of indapamide, 1.5mg sustained release: results of two randomized double-blind controlled studies. J Cardiovasc Pharmacol 1998; 32: 673-8
91. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003
92. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. LIFE Study Investigators. Circulation 2003; 108: 684-90
93. Dahlöf B, Zanchetti A, Diez J, et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-64
94. Devereux RB. Therapeutic options in minimizing left ventricular bypertrophy. Am Heart J 2000; 139: S9-14
95. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
96. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002; 288: 2981-97
97. Zanchetti A, Mancia G. The ALLHAT trial: a verdict or a challenge? [editorial]. J Hypertens 2003; 21: 223
98. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895-9